肥胖与 pembrolizumab 治疗子宫内膜癌的结局之间的关联
Bryanna Patterson1, Nikita Sinha1, Emily Broaddus1
1University of North Carolina, Department of Obstetrics and Gynecology, Chapel Hill, NC 27599, USA.
Gynecologic oncology
|December 11, 2025
概括
肥胖与接受pembrolizumab的子宫内膜癌患者的无进展生存率较差有关. 患有MMRp瘤的肥胖患者的反应率最低,突出显示肥胖是免疫治疗有效性的因素.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症研究 癌症研究
背景情况:
- 子宫内膜癌 (EC) 是一种严重的妇科恶性瘤.
- 布罗利祖马布为高级或复发的EC提供了一个治疗选择.
- 肥胖对不同人群治疗反应的影响需要研究.
研究的目的:
- 为了研究肥胖和pembrolizumab响应之间的关系,在一个种族多样化的队列中,研究高级或复发性EC患者.
- 以身体质量指数 (BMI) 来分析无进展生存率 (PFS) 和总生存率 (OS).
主要方法:
- 对179名先进或复发的EC患者进行了回顾性审查,这些患者接受了pembrolizumab治疗.
- 基线临床,人口和癌症特征的收集.
- 卡普兰-梅尔和考克斯回归分析PFS和OS,用对共变量差异的日志等级测试.
主要成果:
- 较高的BMI与较短的PFS相关 (BMI>40:HR 1.91;BMI 30-40:HR 1.55).
- 肥胖与不匹配修复能力 (MMRp) 瘤 (23.4%与40.0%) 的反应率较低有关,但与不匹配修复能力 (MMRd) 瘤无关.
- 与非肥胖的白人患者相比,接受 pembrolizumab 和 lenvatinib 的肥胖患者 (黑色和白色) 的 PFS 情况更糟.
结论:
- 在接受 pembrolizumab 治疗的EC 患者中,肥胖与PFS 恶化有关.
- 肥胖患者的MMRp瘤显示,免疫疗法反应率最低.
- 需要进一步的研究来了解连接肥胖和免疫治疗结果的生物机制.
更多相关视频
05:42Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
Published on: January 26, 2024
3.1K
14:56Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies
Published on: May 6, 2022
5.0K
相关概念视频
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
221
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
221
01:24Obesity
1.1K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.1K
01:21Drug Dosing: Obese Patients
198
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
198
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
159
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
159